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Background: Aspirin use has been shown to lower incidence and mortality in cancer patients. The aim of this population-based
study was to determine the effect of postdiagnosis low-dose aspirin use on survival of patients with oesophageal cancer.
Methods: Patients with oesophageal cancer (1998–2010) were selected from the Eindhoven Cancer Registry and linked with
outpatient pharmacy data regarding aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs). Users were subdivided into both
prediagnosis and postdiagnosis or only postdiagnosis users. Parametric survival models with an exponential (Poisson) distribution
were used with non-specific death as endpoint.
Results: In this study 560 patients were included. Overall, 157 patients (28.0%) were non-users, 293 patients (52.3%) pre- and
postdiagnosis (89 aspirin and 204 NSAID users) and 110 patients (19.6%) only postdiagnosis users (16 aspirin and 94 NSAID users).
Postdiagnosis aspirin use was associated with overall survival (RR 0.45 (95% CI 0.34–0.60; Po0.001); adjusted rate ratio was 0.42
(95% CI: 0.30–0.57; Po0.001). Postdiagnosis use of NSAIDs was associated with overall survival (RR 0.61 (95% CI 0.49–0.76;o0.001);
however, adjusted analyses did not show a significant association with a rate ratio of 0.84 (95% CI 0.66–1.07; P¼ 0.2).
Conclusions: Our study shows that postdiagnosis aspirin use might be associated with a higher survival rate in oesophageal
cancer patients. A randomised clinical trial is needed to verify our observations of possible postdiagnosis aspirin use benefit.
In 2008 an estimated 482 300 new oesophageal cancer cases and
406 800 oesophageal cancer deaths occurred worldwide (Jemal
et al, 2011). Prognosis of patients with oesophageal cancer is poor;
the 10-year survival rate in all patients is B14% (Dubecz et al,
2012). Regular use of aspirin and other nonsteroidal anti-
inflammatory drugs (NSAIDs) has been shown to have a
chemopreventive effect on the incidence of multiple cancers (Din
et al, 2010; Langley et al, 2011; Algra and Rothwell, 2012; Huang
et al, 2014), including oesophageal cancer (Jayaprakash et al, 2006;
Sadeghi et al, 2008; Abnet et al, 2009). In a meta-analysis by Corley
DA et al regular aspirin and NSAID use showed a protective
association with oesophageal cancer, with summary odds ratios
(95% CI) of 0.50 (0.38–0.66) and 0.75 (0.54–1.00), respectively
(Corley et al, 2003). Also, regular use of aspirin has been shown to
have therapeutic effects on the overall and cancer-specific survival
of several types of cancers (Din et al, 2010; Algra and Rothwell,
2012; Bastiaannet et al, 2012).
Aspirin and NSAIDs are inhibitors of prostaglandin endoper-
oxide synthase 1 and 2 (also known as COX1,2); enzymes involved
in the formation of prostaglandins. However, the exact biological
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mechanisms involved in the anticancer effects of aspirin are still
unknown. Low-dose use of aspirin irreversibly inhibits the
constitutive COX1 expression of circulating platelets. Only high-
dose and frequent aspirin use is believed to be capable of inhibiting
the induced COX2 expression in systemic tissues (Bruno et al,
2012). The expression of COX2 has been shown to be upregulated
in most oesophageal tumours and has prognostic significance
(Zimmermann et al, 1999; Buskens et al, 2002). Experimental data
also showed that inhibition of COX2 expression inhibits cell
proliferation and induces apoptosis in human oesophageal
squamous cell carcinoma in vitro (Zhang et al, 2011). Furthermore,
aspirin has been demonstrated to have COX-independent effects
on tumour cells (Dovizio et al, 2013).
Consequently, aspirin and other non-steroid anti-inflammatory
drugs could have an effect on cancer-specific survival and overall
survival. Cancer-specific survival could be affected not only by
taking aspirin after diagnosis owing to the mimicking of adjuvant
therapy in order to prevent metastases, but also on overall survival
as the cancer-related mortality of oesophageal cancer is high.
A preliminary experimental study showed a beneficial effect of
postoperative use of aspirin on the survival of patients with
oesophageal cancer; the 5-year survival for the aspirin users was
51.2%, for the placebo group 41.0% and for the patients who used
no tablets it was 42.3% (P¼ 0.04 or P¼ 0.029 when the last two
groups were combined) (Liu et al, 2009); however, the results are
still indecisive as no significant survival gain was observed in the
any of the TNM-staging groups. The effect of postdiagnosis use of
aspirin and NSAIDs on overall survival of oesophageal cancer has
not been studied in a population-based study yet. Therefore, the
aim of this observational study is to determine the effect of
postdiagnosis use of aspirin and NSAIDs on the overall survival of
patients with oesophageal cancer, using a combined database
of registered drug use and data from a regional cancer registry (van
Herk-Sukel et al, 2010).
MATERIALS AND METHODS
The Eindhoven Cancer Registry (ECR) is maintained by the
Comprehensive Cancer Centre Netherlands and comprises infor-
mation on newly diagnosed cancer patients in the southeastern
part of the Netherlands. The ECR is served by 10 hospitals in an
area of B2,4 million inhabitants. Patients diagnosed with
oesophageal cancer between 1998 and 2010 were selected from
the ECR with no exclusion criteria. Patients are informed about the
registration and registered unless the patient has objected to be
registered. The Netherlands Cancer Registry is obliged to work
according to the law about protection of privacy data; consent of
the patients for this specific study was not applicable. The data
from the ECR were linked to the central patient database of the
PHARMO Database Network as described elsewhere (van Herk-
Sukel et al, 2010). Data regarding the dispensing of aspirin and
NSAIDs (a single dispensing for aspirin was usually for 90 days, for
NSAIDs 30 days) were extracted from the Outpatient Pharmacy
Database of the PHARMO Database Network. Linkage of cancer
registry data with the municipal population registries, which
document the vital status of their inhabitants, resulted in a reliable
vital status of every patient.
Definition of user. Dispensings of aspirin and NSAIDs were
extracted from the PHARMO Outpatient Pharmacy Database
(see Supplementary Table 1). The majority of dispensings of low-
dose aspirin was 80mg (98.1%); 30mg aspirin was only dispensed
92 times from a total of 4835 dispensings (1.9%). Users were
defined as patients who had at least one dispensing for aspirin or
NSAIDs for at least 14 days. Patients were classified as non-users if
they used any dispensed aspirin or NSAIDs for o14 days.
Frequent users were defined as users that had X30 or X45
dispensings. Besides, we defined a subgroup of frequent users who
had 420 dispensings solely postdiagnosis, irrespective of the
number of dispensings prediagnosis.
In order to divide the users into subgroups, the date of
dispensing was compared with the date of diagnosis. Subsequently,
users were subdivided into both prediagnosis (use of aspirin or
NSAIDs at any time or duration before cancer diagnosis) and
postdiagnosis users, only postdiagnosis users, and a group
containing both groups (postdiagnosis users). Patients were
defined as ‘only postdiagnosis’ if they started using medication
for at least 14 days after diagnosis. Patients were classified as
‘prediagnosis and postdiagnosis’ users if they used a medication
before diagnosis and still used that medication for at least 14 days
after diagnosis. ‘Postdiagnosis users’ were defined as pre- and
postdiagnosis users and only postdiagnosis users combined; thus it
includes all postdiagnosis users, irrespective of when they started
the aspirin or NSAIDs. Some patients (n¼ 113) had both
dispensings for aspirin and (other) NSAIDs; they were included
in the aspirin group when the number of dispensings for aspirin
exceeded the number of dispensings for NSAIDs and vice versa if
the number of dispensings for NSAIDs exceeded the number of
dispensings for aspirin.
Definition of follow-up time. Because the PHARMO Outpatient
Pharmacy database comprises GP or specialist prescribed health-
care products dispensed by the outpatient pharmacy, so drug use of
discharged patients, follow-up time started from 14 days after
diagnosis (T0) of the oesophageal cancer and ended at the last
contact date or time of death. Consequently, all patients who died
within 14 days before T0 were excluded. Time to first dispensing
was defined as the time from T0 to the date of the first dispensing.
Survival analysis. In the overall survival analysis with time-
dependent exposure of aspirin or NSAIDs, patients were defined as
non-users from T0 to the date of first use of aspirin or NSAIDs and
user from date of first use to the last contact or time of death. To
analyse the association of aspirin or NSAID use on overall survival,
parametric survival models with exponential (Poisson) distribution
were used. Non-specific death was coded as event in the survival
analyses. Univariable analyses were performed to assess the
association between aspirin or NSAID use and overall survival
and multivariable models were built to adjust for sex, age,
histological type, location of the tumour, comorbidity, grade,
stage, surgery, chemotherapy and radiotherapy. It was possible to
adjust for the presence of the following comorbidities: lung
diseases, other types of cancer, cardiovascular diseases, hyperten-
sion, cerebrovascular accidents, digestive diseases and diabetes.
We adjusted for these comorbidities by grouping the comorbidities
in none or at least one comorbidity. Furthermore, the survival
analysis was stratified for postdiagnosis aspirin users in prediag-
nosis and postdiagnosis, only postdiagnosis users and a combined
group.
RESULTS
In this observational study 560 patients diagnosed with oesopha-
geal cancer from 1998 to 2010 were included with a follow-up until
December 2011. The patient and tumour characteristics of this
cohort are shown in Table 1. Median age at diagnosis was 66 years
(interquartile range 23–97). Overall, 76% of the patients were
males (n¼ 423) and 24% were females (n¼ 137). In total, 59% of
the patients were diagnosed with adenocarcinoma (n¼ 330) and
33% of the patients were diagnosed with squamous cell carcinoma
(n¼ 190). From all patients 157 patients (28%) were non-users of
any dispensed aspirin and NSAIDs. In total, 204 patients (36%)
and 89 patients (16%) used NSAIDs or aspirin both prediagnosis
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and postdiagnosis, 94 patients (17%) and 16 patients (3%) used
NSAIDs or aspirin only postdiagnosis, respectively.
Table 2 shows the association between patient and tumour
characteristics and aspirin or NSAID use. Patients who used
aspirin only postdiagnosis were younger compared with prediag-
nosis and postdiagnosis users and none users (P¼ 0.005). Half of
the only postdiagnosis aspirin users were diagnosed with early-
stage tumours (stage I and II), in contrast, only 12% and 32% of the
pre and postdiagnosis aspirin users and none users were diagnosed
with stage I or II, respectively. Furthermore, none of the only
postdiagnosis aspirin users were diagnosed with stage IV, whereas
pre and postdiagnosis aspirin users and none users were more
frequently diagnosed with stage IV tumours (25% and 45%,
respectively).
Pre and postdiagnosis NSAIDs users were younger compared
with only postdiagnosis NSAIDs users and none users (P¼ 0.005).
Pre and postdiagnosis NSAIDs users were also more frequently
diagnosed with early-stage tumours (29%) than only postdiagnosis
NSAIDs users (22%) and none users (12%). Only postdiagnosis
NSAIDs users had less stage IV tumours at diagnosis (25%) than
pre and postdiagnosis NSAIDs users (34%) and none users (45%).
No differences were observed in the distribution of the sex of the
patients and the grade of the tumours between the different
subgroups (P40.05).
Survival analysis. Table 3 shows the time-dependent (overall)
survival analysis for non-users and users of aspirin. Median follow-
up time was 0.83 years (range 0–13.83); with a median follow-up
for deceased patients of 0.55 years (range 0–10.54) and 3.30 years
(range 1.0–13.80) for patients still alive at the end of follow-up.
Prediagnosis and postdiagnosis use of aspirin was associated with a
significant survival gain namely in crude analyses (RR 0.55 (95%
CI 0.41–0.74; Po0.001) and in multivariable analyses with an RR
of 0.44 (95% CI: 0.31–0.61; Po0.001) after adjusting for the above-
mentioned confounders. Furthermore, only postdiagnosis aspirin
use was associated with a significant reduction of the overall
mortality rate ratio RR 0.15 (95% CI: 0.07–0.32; Po0.001). After
adjusting for sex, age, grade, stage, histological type, location of the
tumour, treatment and comorbidities the multivariable RR was
0.29 (95% CI: 0.12–0.70; P¼ 0.006). Any postdiagnosis aspirin use
did also result in a significant better survival outcome with a crude
RR of 0.45 (95% CI 0.34–0.60; Po0.001) and an adjusted RR of
0.42 (95% CI: 0.30–0.57; Po0.001). Frequent postdiagnosis users
of430 dispensings showed a crude RR of 0.56 (95% CI 0.39–0.82;
P¼ 0.003) and a similar adjusted RR of 0.49 (95% CI: 0.33–0.73;
Po0.001), whereas frequent users of 445 dispensings showed a
stronger association with an adjusted RR of 0.36 (95% CI: 0.21–
0.62; Po0.001 (crude RR 0.43 (95% CI 0.25–0.73; P¼ 0.002))).
Frequent users of 420 dispensings solely postdiagnosis (irrespec-
tive of the number prediagnosis) showed a lower crude (RR 0.23
(95% CI 0.11–0.50; Po0.001) and adjusted RR of 0.25 (95% CI:
0.11–0.54; Po0.001), although the number of users (n¼ 14) was
low in this group. Figure 1 shows the survival curve of
postdiagnosis aspirin users and none users.
Figure 2 shows the stratified analysis of postdiagnosis aspirin
use. Stratified analysis showed the point estimate of aspirin use is
lower for females adjusted RR 0.24 (95% CI: 0.10–0.55; Po0.001)
than males 0.55 (95% CI: 0.37–0.80; P¼ 0.002). The estimate of
aspirin users compared with non-users when having early-stage
tumours were lower adjusted RR 0.33 (95% CI: 0.15–0.74;
P¼ 0.007) than in patients with late-stage tumours RR 0.56
(95% CI: 0.35–0.89; P¼ 0.01). Moreover, the point estimate in
patients with squamous cell carcinoma adjusted RR 0.34 (95% CI:
0.18–0.63; Po0.001) was lower than in patients with adenocarci-
noma RR 0.43 (95% CI: 0.28–0.65; Po0.001). Furthermore, the
point estimates of aspirin use were lower in patients who
underwent surgery (RR 0.40 (95% CI 0.20–0.79) vs RR 0.45 (95%
CI 0.31–0.66) in patients who did not undergo surgery),
chemotherapy (RR 0.38 (95% CI 0.17–0.86) vs RR 0.43 (95% CI
0.30–0.62) in patients who were not treated with no chemotherapy)
or radiotherapy (RR 0.39 (95% CI 0.26–0.58) vs RR 0.47 (95% CI
0.27–0.84) in patients who were not treated with radiotherapy than
in untreated patients.
Table 3 shows the time-dependent survival analysis for non-
users and users of NSAIDs. Prediagnosis and postdiagnosis use of
NSAIDs did result a significant survival gain with an RR of 0.45
(95% CI: 0.36–0.57; Po0.001). After adjusting for possible
confounders the adjusted mortality rate ratio for prediagnosis
and postdiagnosis NSAIDs use was significant 0.72 (95% CI:
0.55–0.95; P¼ 0.02). Only postdiagnosis NSAIDs use however
was not associated with a better survival outcome in the adjusted
analyses with an RR of 0.81 (95% CI: 0.59–1.11; P¼ 0.2). Any
postdiagnosis NSAIDs was associated with overall survival in
the crude analyses (RR 0.61 (95% CI 0.49–0.78; Po0.001),
however did not result in a significant survival gain in the
multivariable analyses with an adjusted RR of 0.84 (95% CI:
0.66–1.07; P¼ 0.2).
Table 1. Characteristics of the oesophageal cancer patients
included in the cohort
Variable Number Percentage
Sex
Male 423 75.5
Female 137 24.5
Age
o60 164 29.3
60–70 173 30.9
70–80 153 27.3
80þ 70 12.5
Histological type
SCC 190 33.9
AC 330 58.9
Squamo-adenocarcinoma 5 0.9
Other 35 6.3
Localisation
Upper third 23 4.1
Middle third 83 14.8
Lower third 420 75.0
GE-junction 16 2.9
Cervical 10 1.8
Unknown 8 1.4
Stage
I 45 8.0
II 89 15.9
III 104 18.6
IV 186 33.2
Unknown 136 24.3
Grade
I 28 5.0
II 150 26.8
III 215 38.4
Unknown 167 29.8
Surgery
Yes 178 31.8
No 382 68.2
Chemotherapy
Yes 177 31.6
No 383 68.4
Radiotherapy
Yes 328 58.6
No 232 41.4
Abbreviations: AC¼ adenocarcinoma; GE-junction¼gastroesophageal junction; SCC¼
squamous cell carcinoma.
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DISCUSSION
This study shows a possible association between postdiagnosis
aspirin use and overall survival in patients with oesophageal
cancer. Our results are the first to suggest an association of aspirin
use after diagnosis and survival in oesophageal cancer patients.
Studies so far focused on the effect of aspirin and NSAIDs use on
the risk of developing oesophageal cancer. Also, the effect seems to
be aspirin-specific; the postdiagnosis use of NSAIDs had no
Table 2. Differences in patient and tumour characteristics between none user, prediagnosis & postdiagnosis and only
postdiagnosis users of aspirin or NSAIDs
None Pre and postdiagnosis Only postdiagnosis
N (%)a N (%)a N (%)a P-value
Aspirin use
Sex
Male 115 (73.2) 72 (80.9) 11 (68.8) 0.3
Female 42 (26.8) 17 (19.1) 5 (31.2)
Age
o60 40 (25.5) 11 (12.4) 6 (37.5) 0.005
60–70 45 (28.7) 20 (22.5) 5 (31.2)
70–80 42 (26.8) 42 (47.2) 5 (31.2)
80þ 30 (19.1) 16 (18.0) 0 (0.0)
Grade
I 7 (4.5) 5 (5.6) 2 (12.5) 0.7
II 38 (24.2) 26 (29.2) 4 (25.0)
III 65 (41.4) 30 (33.7) 6 (37.5)
Unknown 47 (29.9) 28 (31.5) 4 (25.0)
Stage
I 7 (4.5) 8 (9.0) 2 (12.5) o0.001
II 12 (7.6) 20 (22.5) 6 (37.5)
III 26 (16.6) 13 (14.6) 4 (25.0)
IV 71 (45.2) 22 (24.7) 0 (0.0)
Unknown 41 (26.1) 26 (29.2) 4 (25.0)
Comorbidities
At least one 109 (69.4) 88 (98.9) 9 (56.3) o0.001
Other cancer 22 (14.0) 18 (20.2) 0 (0.0) 0.08
Lung diseases 17 (10.8) 16 (18.0) 1 (6.3) 0.2
Digestive diseases 12 (7.6) 11 (12.4) 2 (12.5) 0.4
Hypertension 28 (17.8) 33 (37.1) 3 (18.8) 0.004
CVA 9 (5.7) 14 (15.7) 0 (0.0) 0.02
CVD 32 (20.4) 60 (67.4) 3 (18.8) o0.001
Diabetes 15 (9.6) 22 (24.7) 1 (6.3) 0.004
NSAIDs use
Sex
Male 115 (73.2) 156 (76.5) 69 (76.4) 0.7
Female 42 (26.8) 48 (23.5) 25 (26.6)
Age
o60 40 (25.5) 78 (38.2) 29 (30.9) 0.005
60–70 45 (28.7) 70 (34.3) 33 (35.1)
70–80 42 (26.8) 43 (21.1) 21 (22.3)
80þ 30 (19.1) 13 (6.4) 11 (11.7)
Grade
I 7 (4.5) 12 (5.9) 2 (2.1) 0.5
II 38 (24.2) 53 (26.0) 29 (30.9)
III 65 (41.4) 83 (40.7) 31 (33.0)
Unknown 47 (29.9) 56 (27.5) 32 (34.0)
Stage
I 7 (4.5) 24 (11.8) 4 (4.3) o0.001
II 12 (7.6) 34 (16.7) 17 (18.1)
III 26 (16.6) 40 (19.6) 21 (22.3)
IV 71 (45.2) 70 (34.3) 23 (24.5)
Unknown 41 (26.1) 36 (17.6) 29 (30.9)
Comorbidities
At least one 109 (69.4) 132 (64.7) 62 (66.0) 0.6
Other cancer 22 (14.0) 31 (15.2) 15 (16.0) 0.9
Lung diseases 17 (10.8) 25 (12.3) 13 (13.8) 0.8
Digestive diseases 12 (7.6) 21 (10.3) 3 (3.2) 0.1
Hypertension 28 (17.8) 43 (21.1) 15 (16.0) 0.5
CVA 9 (5.7) 4 (2.0) 3 (3.2) 0.2
CVD 32 (20.4) 44 (21.6) 17 (18.1) 0.8
Diabetes 15 (9.6) 17 (8.3) 6 (6.4) 0.7
Abbreviations: CVA¼ cerebrovascular accident; CVD¼ cardiovascular disease; NSAIDs¼ nonsteroidal anti-inflammatory drugs.
aData represented here are column percentages within the subgroups.
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significant effect on outcome. Furthermore, the stratified analysis
shows an association of survival with aspirin use consistent among
different subgroups, including gender, age and tumour cell type.
Although our results suggest a consistent survival effect of
aspirin use in patients with adenocarcinoma and squamous cell
carcinoma, the effect might differ between patients with tumours of
a different tumour cell type. It is not clear which mechanisms cause
this difference in effect of low-dose aspirin use. Furthermore, the
survival effect of aspirin use was stronger in only postdiagnosis
aspirin users than in ‘prediagnosis and postdiagnosis’ aspirin users.
It is plausible that tumours that developed in presence of low
plasma levels of aspirin are also not oppressed by low-dose
postdiagnosis aspirin use. The effect might differ between patients
with an early-stage tumour RR 0.33 (95% CI: 0.15–0.74; P¼ 0. 007)
than for late-stage tumours. This might be explained by the
assumed predominant anticancer effect of aspirin. Because the
effect is also seen in the late-stage tumours, the idea that the effect
of aspirin is multifactorial is confirmed (Reimers et al, 2014).
The biological mechanisms involved in the anticancer effect of
aspirin are not (yet) fully understood, but recent evidence points
out a role of platelets. Aspirin inhibits COX1 expression in
platelets, which disrupts platelet activation and the subsequent
secretion of a-granules containing TGF-b and PDGF. These
growth factors are involved in the epithelial–mesenchymal
transition of circulating tumour cells; thus, aspirin might diminish
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Figure 1. Overall survival curve for postdiagnosis use or non-use of
aspirin in patients with oesophageal cancer (pre and postdiagnosis
users and only postdiagnosis users combined).
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Figure 2. Stratified analysis for postdiagnosis aspirin use (pre and
postdiagnosis users and only postdiagnosis users combined).
Table 3. Time-dependent overall survival analysis (crude RR and adjusted RR) for non-users and users of aspirin or NSAIDs
N Ea Crude rate ratio P-value Adjusted rate ratiob P-value
Aspirin pre and postdiagnosis
Non-user 157 129 Reference o0.001 Reference o0.001
User 89 67 0.55 (0.41–0.74) 0.44 (0.31–0.61)
Aspirin only postdiagnosis
Non-user 157 129 Reference o0.001 Reference 0.006
User 16 7 0.15 (0.07–0.32) 0.29 (0.12–0.70)
Aspirin postdiagnosisc
Non-user 157 129 Reference o0.001 Reference o0.001
User 105 74 0.45 (0.34–0.60) 0.42 (0.30–0.57)
Non-user 215 171 Reference 0.003 Reference o0.001
Frequent user (430) 47 32 0.56 (0.39–0.82) 0.49 (0.33–0.73)
Non-user 237 188 Reference 0.002 Reference o0.001
Frequent user (445) 25 15 0.43 (0.25–0.73) 0.36 (0.21–0.62)
Non-user 248 196 Reference o0.001 Reference o0.001
Frequent user postdiagnosis (420) 14 7 0.23 (0.11–0.50) 0.25 (0.11–0.54)
NSAID pre and postdiagnosis
Non-user 157 129 Reference o0.001 Reference 0.02
User 204 146 0.45 (0.36–0.57) 0.72 (0.55–0.95)
NSAID only postdiagnosis
Non-user 157 129 Reference 0.05 Reference 0.2
User 94 76 0.75 (0.57–1.00) 0.81 (0.59–1.11)
NSAID postdiagnosisc
Non-user 157 129 Reference o0.001 Reference 0.2
User 298 222 0.61 (0.49–0.76) 0.84 (0.66–1.07)
Abbreviations: NSAIDs, nonsteroidal anti-inflammatory drugs; RR, rate ratio.
aE¼ number of events.
bAdjusted for sex, age, grade, stage, morphology, histological type, location of the tumour, treatment and comorbidities.
cPre and postdiagnosis and only postdiagnosis users combined.
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the metastatic potential (Labelle et al, 2011; Lou et al, 2014).
Furthermore, aspirin use might also induce COX-independent
effects on platelets, for example, by the acetylation of proteins and
metabolites, and these other mechanisms could be involved in the
chemopreventive effect of aspirin (Dovizio et al, 2013).
Recently, several molecular epidemiological studies have been
performed to identify the subset of patients with colorectal cancer
who will benefit from aspirin by chemoprevention or as adjuvant
therapy and showed in two studies that the observed significant
survival gain of postdiagnosis aspirin use was present in mutated-
PIK3CA tumours, but not in PIK3CA wild-type tumours (Liao et al,
2012; Domingo et al, 2013). However, PGTS2-specific inhibition by
rofecoxib did not improve the relapse-free survival in PIK3CA-
mutated tumours (P¼ 0.66) (Domingo et al, 2013). In contrast, the
analysis of 999 colorectal tumour blocks resected from 2002 to 2008
in the Netherlands showed no association of survival benefit of
postdiagnosis use of aspirin with tumours with mutated-PIK3CA
and COX2 expression. The survival benefit of low-dose postdiag-
nosis aspirin use did depend on the presence of another biomarker;
patients with tumours with HLA Class I antigen expression showed
a significant survival gain, but patients with tumours without HLA
Class I antigen expression did not (Reimers et al, 2014).
The value of PIK3CA-mutation status and COX2 expression
levels as biomarkers in colon cancer remains inconclusive (Liao
et al, 2012; Reimers et al, 2014). Also, the mutation frequency of
PIK3CA in oesophageal squamous cell carcinomas and adenocar-
cinomas is lower, namely 4.5% (Song et al, 2014), respectively,
6.0% (Phillips et al, 2006) than the reported mutation rates of
11–17% (Liao et al, 2012; Nishihara et al, 2013; Rosty et al, 2013;
Reimers et al, 2014) in the tumour specimens of colorectal
carcinomas. Therefore, future molecular pathological epidemiolo-
gical studies should focus on a combination of potential
biomarkers to examine the therapeutic effect of postdiagnosis
aspirin use in patients with oesophageal cancer.
The present observational study has several limitations. First, as
baseline characteristics (which are associated with survival) of non-
users and aspirin users differ, the survival effect of aspirin could
also partially be caused by healthy-user bias. As shown in Table 1,
the users are younger and have a lower stage of disease at the
moment of diagnosis, which are associated with survival; however,
they are also more often diagnosed with comorbidities. We
adjusted for these factors in the multivariable analyses, but residual
confounding may be present and as a result of the lower number of
users it remains questionable if we adjusted sufficiently, especially
in the group of ‘only postdiagnosis’ users. However, the survival
analysis of the ‘prediagnosis and postdiagnosis’ also resulted in a
strong survival effect with an adjusted RR of 0.44 (95% CI: 0.31–
0.61). The analyses of frequent users showed a stronger association
in frequent users, although only present in the users with a high
number of dispensings. A second limitation of the present study is
the low number of ‘only postdiagnosis’ aspirin users in the patient
cohort, which might influence the results. Larger studies with a
higher number of postdiagnosis aspirin users are needed to
confirm the results. A third limitation of the study could be ‘over
the counter use’ of aspirin. However, low-dose aspirin is mainly
available on dispensing in the Netherlands, but we cannot rule out
the possibility of over the counter use of (higher) aspirin doses,
which are available as we did not have information regarding the
use of aspirin or NSAIDs by patients at home. At last, aspirin is
usually prescribed by the means of cardiovascular chemopreven-
tion, thus confounding by indication could be a problem. It is
however not likely that the indicators of an elevated risk of
cardiovascular disease provide user patients with a beneficial
survival prognosis with respect to non-user patients. Also, the
survival effect of aspirin use cannot only be explained by a
reduction of cardiac events; in the meta-analysis of six primary
prevention trials and 16 secondary prevention trials by Baigent C
et al the survival gain of aspirin use was lower than the survival
gain observed in the present study and showed a pooled gain (for
primary and secondary prevention of vascular disease) of B5%
(Baigent et al, 2009). One of the major strengths of our study was
the use of a database of dispensed medication, by which we avoided
recall-bias.
Our study suggests that patients with oesophageal cancer might
benefit more from postdiagnosis aspirin use than patients with
colon cancer. These results are in line with previous data of
Rothwell’s study of the long-term risk of cancer-related death in
daily aspirin users; the 20-year cancer-related mortality was lower
for patients with oesophageal cancer 0.42 (95% CI: 0.25–0.71) than
for patients with colon cancer 0.60 (95% CI: 0.45–0.81) (Rothwell
et al, 2011).
In the future, a randomised clinical trial is needed to verify our
epidemiological observations of the benefits of postdiagnosis
aspirin use in patients with oesophageal cancer. Furthermore, it
is important to identify the subgroups in which the benefits of low-
dose postdiagnosis aspirin might outweigh the risks of severe
adverse effects like gastrointestinal bleeding. The identification of
biomarkers could predict in which patients low-dose aspirin has a
significant survival effect. Because aspirin is already a well-tested
and cheap drug, it could have a beneficial clinical impact when
introduced as an adjuvant therapy in patients with oesophageal
cancer.
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